Format

Send to

Choose Destination
Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Author information

1
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
2
Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA jgainor@partners.org.

Abstract

Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoints have been cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein-1 (PD-1) pathway. In early studies, PD-1/programmed cell death ligand-1 (PD-L1) inhibitors demonstrated promising antitumor activity and durable clinical responses in a subset of patients. Based on these encouraging results, multiple different PD-1/PD-L1 inhibitors have entered clinical development, and two agents (nivolumab and pembrolizumab) have gained regulatory approval in the United States for the treatment of NSCLC. In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. In the present report, we provide an overview of the rationale for checkpoint inhibitors in lung cancer, recent clinical trial data, and the need for predictive biomarkers.

THE ONCOLOGIST:

2017;22:81-88 IMPLICATIONS FOR PRACTICE: Strategies targeting negative regulators (i.e., checkpoints) of the immune system have demonstrated significant antitumor activity across a range of solid tumors. In non-small cell lung cancer (NSCLC), programmed cell death protein-1 (PD-1) pathway inhibitors have entered routine clinical use because of the results from recent randomized studies demonstrating superiority against single-agent chemotherapy in previously treated patients. The present report provides an overview of immune checkpoint inhibitors in lung cancer for the practicing clinician, focusing on the rationale for immunotherapy, recent clinical trial data, and future directions.

KEYWORDS:

Checkpoint inhibition; Cytotoxic T‐lymphocyte‐associated antigen 4; Immune therapy; Lung cancer; Non‐small cell lung cancer; Programmed cell death protein‐1 inhibitors

PMID:
27534574
PMCID:
PMC5313266
DOI:
10.1634/theoncologist.2016-0189
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center